Once-daily dolutegravir is non-inferior to twice-daily raltegravir in treatment-naïve adults with HIV-1
27 July 2012 | By GlaxoSmithKline
Findings support progression towards registration...
List view / Grid view
News
pSivida announces ILUVIEN® marketing authorisation in Germany
27 July 2012 | By pSivida Corp.
For the treatment of vision impairment associated with chronic diabetic macular edema...
Luitpold Pharmaceuticals, Inc. receives complete response letter for Injectafer® from the U.S. FDA
26 July 2012 | By Daiichi Sankyo
Luitpold Pharmaceuticals submitted a New Drug Application to the U.S. FDA...
FDA clears Roche’s vitamin D laboratory test
26 July 2012 | By Roche
Fully automated assay for widely available platforms offers labs efficient solution to help assess patient vitamin D levels...
Results announcement for the second quarter 2012
25 July 2012 | By GlaxoSmithKline
GSK delivers Q2 core EPS of 26.4p and dividend of 17p...
Sanofi Pasteur’s dengue vaccine demonstrates proof of efficacy
25 July 2012 | By Sanofi Pasteur
Early data analysis confirms excellent safety profile...
Lundbeck disagrees with the Statement of Objections issued by the European Commission
25 July 2012 | By H. Lundbeck A/S
The European Commission has issued a Statement of Objections to Lundbeck...
Jentadueto® tablets receive approval for the treatment of adults with Type 2 Diabetes in Europe
25 July 2012 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) received Marketing Authorisation from the European Commission for Jentadueto® which combines the DPP-4 inhibitor, linagliptin and metformin in a single tablet. 1 Linagliptin/metformin hydrochloride (HCl) will provide a new, single-tablet treatment option, taken twice-daily, for adults with Type 2 Diabetes. 1
Merck collaborators publish study showing potential for eradication of persistent HIV virus in the body
25 July 2012 | By Merck
Merck announced the publication of a study...
Astellas initiates head-to-head study comparing QUTENZA™ and pregabalin
24 July 2012 | By Pegasus
The first study to compare the 8% capsaicin patch with pregabalin...
Merck signs two deals for novel HIV drug candidates and initiates Phase II clinical trial of MK-1439 for HIV
24 July 2012 | By Merck
Merck remains committed to advancing treatment for people with HIV...
Gilead ’s Boosting Agent Cobicistat for HIV Therapy as Effective as Ritonavir in Pivotal Phase 3 Study
24 July 2012 | By Gilead Sciences, Inc.
Full clinical trial results from a pivotal Phase 3 study...
Topline results of first of four studies in bapineuzumab Phase 3 program
23 July 2012 | By Pfizer
Co-primary clinical endpoints not met in study of patients with Alzheimer’s disease who carry the ApoE4 genotype...
Video: New data gives hope to rheumatoid arthritis patients
23 July 2012 | By Roche
Almost four times as many patients achieve remission with RoActemra (tocilizumab) compared to Humira (adalimumab)...
Boehringer Ingelheim and Funxional Therapeutics announce acquisition of Funxional’s FX125L and the somatotaxin portfolio to treat inflammation
23 July 2012 | By Boehringer Ingelheim
FX125L is a small molecule...
